$8.75
2.23% yesterday
Nasdaq, Jun 09, 10:00 pm CET
ISIN
US19207A1088
Symbol
COEP
Sector
Industry

Coeptis Therapeutics Stock price

$8.75
-0.75 7.89% 1M
+5.03 135.34% 6M
+3.25 59.09% YTD
+3.23 58.51% 1Y
-189.25 95.58% 5Y
-189.25 95.58% 10Y
-189.25 95.58% 20Y
Nasdaq, Closing price Mon, Jun 09 2025
-0.20 2.23%
ISIN
US19207A1088
Symbol
COEP
Sector
Industry

Key metrics

Market capitalization $30.75m
Enterprise Value $30.41m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 4.03
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-21.22m
Free Cash Flow (TTM) Free Cash Flow $-7.24m
Cash position $1.47m
EPS (TTM) EPS $-12.39
P/E forward negative
Short interest 1.08%
Show more

Is Coeptis Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,824 stocks worldwide.

Coeptis Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Coeptis Therapeutics:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Coeptis Therapeutics:

Buy
100%

Financial data from Coeptis Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '23
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 15 15
-
-
- Research and Development Expense 6.40 6.40
-
-
-20 -20
-
-
- Depreciation and Amortization 1 1
-
-
EBIT (Operating Income) EBIT -21 -21
67% 67%
-
Net Profit -21 -21
69% 69%
-

In millions USD.

Don't miss a Thing! We will send you all news about Coeptis Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Coeptis Therapeutics Stock News

Neutral
GlobeNewsWire
13 days ago
WEXFORD, Pa. and PRINCETON, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- SNAP Biosciences, Inc a majority-owned subsidiary of Coeptis Therapeutics Holdings Inc. (Nasdaq: COEP) and Monarch Therapeutics Inc., a biotechnology company pioneering next-generation immunotherapies, today announced a licensing agreement to enable the development and commercialization of SNAP Biosciences' proprietary Snap-Car ...
Neutral
GlobeNewsWire
about one month ago
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Neutral
Business Wire
about 2 months ago
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) and Z Squared Inc. is fair to Coeptis shareholders. Halper Sadeh encourages Coeptis shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@ha...
More Coeptis Therapeutics News

Company Profile

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company. It develops innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. The firm's products include CD38-GEAR-NK, CD38-Diagnostic and GEAR-NK Product. The company was founded in 2017 and is headquartered in Wexford, PA.

Head office United States
CEO David Mehalick
Employees 6
Founded 2017
Website coeptistx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today